Actithera Secures $75.5M in Series A to Push Radioligand Therapy Boundaries
Deal News | Sep 07, 2025 | Bioqube Ventures NV
Actithera, a burgeoning radiopharmaceutical biotech company, has announced an impressive close to its Series A financing round, amassing $75.5 million. Spearheaded by Bioqube Ventures NV., this oversubscribed round underscores growing investor confidence in the firm's potential to revolutionize precision radioligand therapies (RLTs). Actithera plans to channel these funds into advancing its leading Fibroblast Activation Protein (FAP) asset into clinical development across multiple disease indications. This ambitious stride seeks to harness Actithera’s unique medicinal chemistry insights for next-generation RLTs. Situated at the crossroads of Oslo, Norway and Cambridge, Massachusetts, Actithera is poised to be an influential player in the field of targeted cancer therapeutics, aiming to make significant breakthroughs in precision oncology.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- Norway – Oslo, Norway is noted as one of the significant operational locations of Actithera, contributing to its geographical relevance.
- United States – Cambridge, Massachusetts is highlighted as another key location for Actithera, indicating a transatlantic operational base.
Industry
- Biotechnology – Actithera operates within the biotechnology sector, focusing specifically on the development of radiopharmaceutical therapies aimed at cancer treatment.
- Pharmaceuticals – The article involves the pharmaceutical sector as Actithera is advancing radioligand therapies, which are a form of pharmaceutical development targeted at medical treatment.
Financials
- $75.5 million – The amount raised by Actithera in its Series A financing round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Actithera | Biotech Company | Target Company | Actithera is the radiopharmaceutical biotech firm raising $75.5 million to develop next-generation radioligand therapies. |
| Bioqube Ventures NV. | Lead Investor | PE Firm | Bioqube Ventures NV. led the $75.5 million Series A funding round for Actithera. |